COMP <GO>
IDXX vs MRK // RETURN ON INVESTED CAPITAL (ROIC)
IDEXX Laboratories Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: IDXX 5
— MRK 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: IDXX
LAST: $551.21 (-4.30%) • MKT CAP: $45.38B
roic
29.60%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
roic
20.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDXX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IDXX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.80% | 74.80% | -13.00 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 29.60% | 20.70% | +8.90 | IDXX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 31.1x | 15.3x | +15.80 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 3.42% | -1.09 | MRK | /fcf-yield <GO> |
| Operating Margin | 31.60% | 34.30% | -2.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | 24.60% | 28.10% | -3.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | 1.30% | +9.10 | IDXX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 20.99 | 5.19 | +15.80 | IDXX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | IDXX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.50% | 6.60% | -0.10 | IDXX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 52.4 | 56.9 | -4.47 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 0.92 | -0.03 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.8x | 18.4x | +21.40 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $45.38B | $361.02B | -$315.64B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IDXX REV | MRK REV | IDXX GROSS % | MRK GROSS % | IDXX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.30B | $65.01B | 61.8% | 74.8% | $1.06B | $12.36B |
| FY 2024 | $3.90B | $64.17B | 61.0% | 76.3% | $808.1M | $18.10B |
| FY 2023 | $3.66B | $60.12B | 44.0% | 44.0% | $741.8M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDXX // BETA 0.89
MRK // BETA 0.92